Accept Rs 700-cr from UAE or compensate us: Flood-ravaged Kerala tells Modi govt

Bengaluru, Jul 13:  Karnataka Deputy chief minister Dr CN Ashwath Narayan on Monday urged chief minister BS Yediyurappa to cancel the license of private hospitals and private medical colleges which did not hand over their 50 per cent beds, to the government, Karnataka Deputy Chief Minister's Office said.

On June 26, the Karnataka government reserved about 50 per cent for COVID-19 patients in some private hospitals in Bengaluru.

Earlier in the day, former Karnataka Chief Minister HD Kumaraswamy said that the state government should provide vitamin C drug, Ayush Ministry-certified immunity boosters and sanitisers to every household in the wake of the coronavirus spread.

According to the Union Health Ministry, Karnataka has recorded 38,843 cases of COVID-19 to date.

Bengaluru, Jan 21: A massive protest against the Citizenship Amendment Act (CAA), National Register of Citizens (NRC), and National Population Register (NPR) was witnessed at Shivajinagar's Chandni Chowk area on Tuesday.

Scores of people came together carrying national flags and placards to register their protest in the city.

Speaking to ANI, a protester said, "People of all religious community have assembled here in Chandni Chowk to protest against CAA, NRC, and NPR. We the people of India are against this law."

Terming the law as anti-constitutional, he said that we support all the states who oppose the CAA. We demand the revocation of CAA and the government should remove conditions in NPR which lead to NRC.

CAA grants citizenship to Hindu, Sikh, Jain, Parsi, Buddhist and Christian communities fleeing religious persecution from Pakistan, Afghanistan, and Bangladesh and who came to India on or before December 31, 2014.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.